Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Circulation Research Year : 2012

Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions.

Nicole M. Thielens


RATIONALE: A noninvasive tool allowing the detection of vulnerable atherosclerotic plaques is highly needed. By combining nanomolar affinities and fast blood clearance, nanobodies represent potential radiotracers for cardiovascular molecular imaging. Vascular cell adhesion molecule-1 (VCAM1) constitutes a relevant target for molecular imaging of atherosclerotic lesions. OBJECTIVE: We aimed to generate, radiolabel, and evaluate anti-VCAM1 nanobodies for noninvasive detection of atherosclerotic lesions. METHODS AND RESULTS: Ten anti-VCAM1 nanobodies were generated, radiolabeled with technetium-99m, and screened in vitro on mouse and human recombinant VCAM1 proteins and endothelial cells and in vivo in apolipoprotein E-deficient (ApoE(-/-)) mice. A nontargeting control nanobody was used in all experiments to demonstrate specificity. All nanobodies displayed nanomolar affinities for murine VCAM1. Flow cytometry analyses using human human umbilical vein endothelial cells indicated murine and human VCAM1 cross-reactivity for 6 of 10 nanobodies. The lead compound cAbVCAM1-5 was cross-reactive for human VCAM1 and exhibited high lesion-to-control (4.95±0.85), lesion-to-heart (8.30±1.11), and lesion-to-blood ratios (4.32±0.48) (P<0.05 versus control C57Bl/6J mice). Aortic arch atherosclerotic lesions of ApoE(-/-) mice were successfully identified by single-photon emission computed tomography imaging. (99m)Tc-cAbVCAM1-5 binding specificity was demonstrated by in vivo competition experiments. Autoradiography and immunohistochemistry further confirmed cAbVCAM1-5 uptake in VCAM1-positive lesions. CONCLUSIONS: The (99m)Tc-labeled, anti-VCAM1 nanobody cAbVCAM1-5 allowed noninvasive detection of VCAM1 expression and displayed mouse and human cross-reactivity. Therefore, this study demonstrates the potential of nanobodies as a new class of radiotracers for cardiovascular applications. The nanobody technology might evolve into an important research tool for targeted imaging of atherosclerotic lesions and has the potential for fast clinical translation.
Fichier principal
Vignette du fichier
Broisat_-_Imaging_Atherosclerosis_with_anti-VCAM-1_nanobodies_HAL.pdf (1.02 Mo) Télécharger le fichier
Broisat_-_Imaging_Atherosclerosis_with_anti-VCAM-1_nanobodies_-_supplements_HAL.doc (1.02 Mo) Télécharger le fichier
inserm-00831749_edited.pdf (595.36 Ko) Télécharger le fichier
Origin Files produced by the author(s)
Format Other
Origin Files produced by the author(s)

Dates and versions

inserm-00831749 , version 1 (07-06-2013)



Alexis Broisat, Sophie Hernot, Jakub Toczek, Jens de Vos, Laurent M. Riou, et al.. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions.: Imaging Atherosclerosis with Anti-VCAM1 Nanobodies. Circulation Research, 2012, 110 (7), pp.927-37. ⟨10.1161/CIRCRESAHA.112.265140⟩. ⟨inserm-00831749⟩
539 View
1113 Download



Gmail Mastodon Facebook X LinkedIn More